A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients.

MLA

Rossi, Sara, et al. “A Novel Potent Class I HDAC Inhibitor Reverses the STAT4/P66Shc Apoptotic Defect in B Cells from Chronic Lymphocytic Leukemia Patients.” Biomedicine & Pharmacotherapy, vol. 174, May 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.biopha.2024.116537.

APA

Rossi, S., Tatangelo, V., Dichiara, M., Butini, S., Gemma, S., Brogi, S., Pasquini, S., Cappello, M., Vincenzi, F., Varani, K., Lopresti, L., Malchiodi, M., Carrara, C., Gozzetti, A., Bocchia, M., Marotta, G., Patrussi, L., Carullo, G., Baldari, C. T., & Campiani, G. (2024). A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients. Biomedicine & Pharmacotherapy, 174, N.PAG. https://doi.org/10.1016/j.biopha.2024.116537

Chicago

Rossi, Sara, Vanessa Tatangelo, Maria Dichiara, Stefania Butini, Sandra Gemma, Simone Brogi, Silvia Pasquini, et al. 2024. “A Novel Potent Class I HDAC Inhibitor Reverses the STAT4/P66Shc Apoptotic Defect in B Cells from Chronic Lymphocytic Leukemia Patients.” Biomedicine & Pharmacotherapy 174 (May): N.PAG. doi:10.1016/j.biopha.2024.116537.